United Therapeutics Corporation (UTHR)
NASDAQ: UTHR · Real-Time Price · USD
284.27
+0.18 (0.06%)
At close: Jun 27, 2025, 4:00 PM
284.12
-0.15 (-0.05%)
After-hours: Jun 27, 2025, 5:34 PM EDT
United Therapeutics Revenue
United Therapeutics had revenue of $794.40M in the quarter ending March 31, 2025, with 17.22% growth. This brings the company's revenue in the last twelve months to $2.99B, up 19.85% year-over-year. In the year 2024, United Therapeutics had annual revenue of $2.88B with 23.63% growth.
Revenue (ttm)
$2.99B
Revenue Growth
+19.85%
P/S Ratio
4.35
Revenue / Employee
$230,315,385
Employees
13
Market Cap
12.82B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2.88B | 549.90M | 23.63% |
Dec 31, 2023 | 2.33B | 391.20M | 20.20% |
Dec 31, 2022 | 1.94B | 250.80M | 14.88% |
Dec 31, 2021 | 1.69B | 202.20M | 13.63% |
Dec 31, 2020 | 1.48B | 34.50M | 2.38% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
UTHR News
- 4 days ago - United Therapeutics and Intermountain Health Announce the First Patient Treated With External Liver Support Using a Bioengineered Liver - Business Wire
- 5 days ago - United Therapeutics Corporation Concludes Enrollment of the ADVANCE OUTCOMES Study of Ralinepag for the Treatment of Pulmonary Arterial Hypertension - Business Wire
- 16 days ago - United Therapeutics: Tanking On Rival's PAH Data - I'd Consider Buying Stock - Seeking Alpha
- 2 months ago - United Therapeutics Corporation (UTHR) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - United Therapeutics Corporation Reports First Quarter 2025 Financial Results - Business Wire
- 2 months ago - United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the American Thoracic Society 2025 International Conference - Business Wire
- 3 months ago - United Therapeutics Corporation to Feature Clinical Data Across its Commercial and Development Portfolio at the International Society for Heart and Lung Transplantation 45th Annual Meeting and Scientific Sessions - Business Wire
- 3 months ago - United Therapeutics: Don't Fear The Patent Expiration Too Much - Seeking Alpha